WO2015166042A1 - Stilbene derivatives and their use for the treatment of cancer - Google Patents
Stilbene derivatives and their use for the treatment of cancer Download PDFInfo
- Publication number
- WO2015166042A1 WO2015166042A1 PCT/EP2015/059502 EP2015059502W WO2015166042A1 WO 2015166042 A1 WO2015166042 A1 WO 2015166042A1 EP 2015059502 W EP2015059502 W EP 2015059502W WO 2015166042 A1 WO2015166042 A1 WO 2015166042A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- cancer
- hydrogen
- alkoxy
- aliphatic
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 65
- 201000011510 cancer Diseases 0.000 title claims abstract description 49
- 238000011282 treatment Methods 0.000 title claims abstract description 29
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical class C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 99
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 86
- 239000001257 hydrogen Substances 0.000 claims abstract description 51
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 49
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 43
- 150000002431 hydrogen Chemical group 0.000 claims abstract description 34
- 125000001931 aliphatic group Chemical group 0.000 claims abstract description 30
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 26
- 150000002367 halogens Chemical group 0.000 claims abstract description 26
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 19
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 19
- 230000002265 prevention Effects 0.000 claims abstract description 19
- 125000003282 alkyl amino group Chemical group 0.000 claims abstract description 18
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 18
- 125000003118 aryl group Chemical group 0.000 claims abstract description 13
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims abstract description 10
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims abstract description 10
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims abstract description 10
- 210000000481 breast Anatomy 0.000 claims abstract description 10
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 10
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract description 9
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract description 9
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 9
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 9
- 229940088597 hormone Drugs 0.000 claims abstract description 9
- 239000005556 hormone Substances 0.000 claims abstract description 9
- 206010014733 Endometrial cancer Diseases 0.000 claims abstract description 8
- 206010014759 Endometrial neoplasm Diseases 0.000 claims abstract description 8
- 208000002495 Uterine Neoplasms Diseases 0.000 claims abstract description 8
- 230000002357 endometrial effect Effects 0.000 claims abstract description 8
- 230000002611 ovarian Effects 0.000 claims abstract description 8
- 206010046766 uterine cancer Diseases 0.000 claims abstract description 8
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims abstract description 7
- 125000004001 thioalkyl group Chemical group 0.000 claims abstract 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 39
- 239000000203 mixture Substances 0.000 claims description 37
- -1 cisplatin Chemical class 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 20
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 19
- 229960004316 cisplatin Drugs 0.000 claims description 19
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 10
- 239000003085 diluting agent Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 6
- 229940123237 Taxane Drugs 0.000 claims description 5
- 229940127073 nucleoside analogue Drugs 0.000 claims description 3
- 150000003058 platinum compounds Chemical class 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 46
- 101100497948 Caenorhabditis elegans cyn-1 gene Proteins 0.000 description 44
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 24
- 125000004432 carbon atom Chemical group C* 0.000 description 22
- 239000003112 inhibitor Substances 0.000 description 18
- 239000000843 powder Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 14
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 14
- 102000015694 estrogen receptors Human genes 0.000 description 14
- 108010038795 estrogen receptors Proteins 0.000 description 14
- 150000003839 salts Chemical class 0.000 description 14
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 239000000758 substrate Substances 0.000 description 12
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 229960005309 estradiol Drugs 0.000 description 11
- 229930182833 estradiol Natural products 0.000 description 11
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 108010078554 Aromatase Proteins 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 125000001188 haloalkyl group Chemical group 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 239000002246 antineoplastic agent Substances 0.000 description 7
- 239000003886 aromatase inhibitor Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- CPRRHERYRRXBRZ-SRVKXCTJSA-N methyl n-[(2s)-1-[[(2s)-1-hydroxy-3-[(3s)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate Chemical group COC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)C[C@@H]1CCNC1=O CPRRHERYRRXBRZ-SRVKXCTJSA-N 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- 108010074918 Cytochrome P-450 CYP1A1 Proteins 0.000 description 6
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 6
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical group [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 6
- 229940046844 aromatase inhibitors Drugs 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 239000000262 estrogen Substances 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 229960003604 testosterone Drugs 0.000 description 6
- 102100029361 Aromatase Human genes 0.000 description 5
- 101710197851 B1 protein Proteins 0.000 description 5
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 description 5
- 102100031476 Cytochrome P450 1A1 Human genes 0.000 description 5
- 229930012538 Paclitaxel Natural products 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 229940127089 cytotoxic agent Drugs 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 229960001592 paclitaxel Drugs 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000001589 microsome Anatomy 0.000 description 4
- 150000007530 organic bases Chemical class 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 230000001172 regenerating effect Effects 0.000 description 4
- 238000013207 serial dilution Methods 0.000 description 4
- 229910021642 ultra pure water Inorganic materials 0.000 description 4
- 239000012498 ultrapure water Substances 0.000 description 4
- CRCWUBLTFGOMDD-UHFFFAOYSA-N 7-ethoxyresorufin Chemical compound C1=CC(=O)C=C2OC3=CC(OCC)=CC=C3N=C21 CRCWUBLTFGOMDD-UHFFFAOYSA-N 0.000 description 3
- 102000014654 Aromatase Human genes 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 229940124639 Selective inhibitor Drugs 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 230000000711 cancerogenic effect Effects 0.000 description 3
- 231100000315 carcinogenic Toxicity 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 238000012261 overproduction Methods 0.000 description 3
- 230000001817 pituitary effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 150000001629 stilbenes Chemical class 0.000 description 3
- 235000021286 stilbenes Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 210000005253 yeast cell Anatomy 0.000 description 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 description 2
- 230000007067 DNA methylation Effects 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 241000792859 Enema Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000006771 Gonadotropins Human genes 0.000 description 2
- 108010086677 Gonadotropins Proteins 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 101000725164 Homo sapiens Cytochrome P450 1B1 Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 2
- 239000007984 Tris EDTA buffer Substances 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 229940122803 Vinca alkaloid Drugs 0.000 description 2
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000004479 aerosol dispenser Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 239000003817 anthracycline antibiotic agent Substances 0.000 description 2
- 230000003432 anti-folate effect Effects 0.000 description 2
- 229940127074 antifolate Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 229960004630 chlorambucil Drugs 0.000 description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000003366 endpoint assay Methods 0.000 description 2
- 239000007920 enema Substances 0.000 description 2
- 229940079360 enema for constipation Drugs 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 239000004052 folic acid antagonist Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000002622 gonadotropin Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
- 229960004768 irinotecan Drugs 0.000 description 2
- 238000003367 kinetic assay Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 235000010603 pastilles Nutrition 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 229960004432 raltitrexed Drugs 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- LDDMACCNBZAMSG-BDVNFPICSA-N (2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-2-(methylamino)hexanal Chemical compound CN[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO LDDMACCNBZAMSG-BDVNFPICSA-N 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- OIPHWUPMXHQWLR-UHFFFAOYSA-N 2-pyridin-3-ylacetonitrile Chemical compound N#CCC1=CC=CN=C1 OIPHWUPMXHQWLR-UHFFFAOYSA-N 0.000 description 1
- QOZFCKXEVSGWGS-ZHIYBZGJSA-N 4-hydroxy-17beta-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1O QOZFCKXEVSGWGS-ZHIYBZGJSA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 229940122815 Aromatase inhibitor Drugs 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 101150042514 B1 gene Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- DLDHZVHOYLJESH-ZQPUQZQPSA-N C/C(/C(Cc(cccc1)c1OC)C#N)=C\C=C/N=C Chemical compound C/C(/C(Cc(cccc1)c1OC)C#N)=C\C=C/N=C DLDHZVHOYLJESH-ZQPUQZQPSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 101000904177 Clupea pallasii Gonadoliberin-1 Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102000008142 Cytochrome P-450 CYP1A1 Human genes 0.000 description 1
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- 102100027417 Cytochrome P450 1B1 Human genes 0.000 description 1
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- FBEXVJVGHFAPDB-NTEUORMPSA-N N#C/C(/c1cccnc1)=C\c1ccccc1 Chemical compound N#C/C(/c1cccnc1)=C\c1ccccc1 FBEXVJVGHFAPDB-NTEUORMPSA-N 0.000 description 1
- 150000007945 N-acyl ureas Chemical class 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 101150053185 P450 gene Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000005899 aromatization reaction Methods 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 125000004452 carbocyclyl group Chemical group 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 231100000573 exposure to toxins Toxicity 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 150000004820 halides Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000008309 hydrophilic cream Substances 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000000575 proteomic method Methods 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 229940100611 topical cream Drugs 0.000 description 1
- 229940100615 topical ointment Drugs 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N trans-stilbene Chemical class C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/57—Nitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
The present application relates to a compound of formula (I) wherein each of R1, R2, R3, R4 or R5 are independently selected from hydrogen, aliphatic, alkoxy, thioalkyl, alkylamino, halogen, hydroxy, cyano, nitro, hydroxyalkyl, alkylcarbonyloxy, alkoxycarbonyl, alkylcarbonyl, haloalkyi, alkylsulfonylamino NH2, NO2, SO2Rx, SORx and COORx, where Rx is hydrogen, aliphatic or aryl, for use in the prevention and/or treatment of cancer. The compounds are particularly provided for the prevention and/or treatment of hormone-induced cancers, such as breast, ovarian, uterine, endometrial and prostate cancer.
Description
STILBENE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER
The present invention relates to compounds for use in the prevention and/or treatment of cancer. Cytochrome P450 (CYP) enzymes belong to a large family of detoxification enzymes that are present in different organs of the human body. The CYP isoform CYP1 B1 has been found to be expressed in all cancers, regardless of oncogenic origin, while being absent from healthy tissue. It is understood that CYP1 B1 may have a dominant role in the genesis of breast cancer.
Activated estrogen receptor (ER) is responsible for breast cell division (proliferation). ER is activated by its ligand, estradiol (a steroidal hormone). In pre-menopausal women, estradiol is primarily produced in the ovaries by the pituitary via a cascade of biochemical reactions initiated by the LH-RH receptor whereas, in post-menopausal women, estradiol is synthesised solely in the adrenal glands from testosterone. Hyper-activated ER, through constant overproduction of estradiol, is the cause of ER-positive breast cancers and 80% of breast cancers are ER-positive. It is thought that preventing the synthesis of the ER ligand, estradiol, could lead to an ideal treatment of ER-positive breast cancers. However, estradiol plays an essential role in most healthy tissues.
Estradiol is synthesised through the aromatisation of the 'A' ring of testosterone with the help of cytochrome P450 19 (CYP19) enzyme which is also known as aromatase. The CYP19 enzyme (i.e. aromatase) catalyses the conversion of testosterone to estradiol. Inhibitors of aromatase have been hugely successful for the treatment of estrogen receptor (ER)-positive post-menopausal breast cancers. Unfortunately the use of aromatase inhibitors is restricted to the treatment of post-menopausal women suffering from breast cancer. The inhibitors avert the formation of estradiol from testosterone thereby inhibiting cell division by preventing activation of ER. However, aromatase inhibitors have profound adverse effects on pre-menopausal ER-positive breast cancer patients, as a result of a biochemical feedback loop that affects the pituitary.
In particular, the use of aromatase inhibitors in premenopausal women, results in a decrease in estrogen, which activates the hypothalamus and pituitaries to increase
gonadotropin secretion, which in turn stimulates the ovary to increase testosterone production. The heightened gonadotropin levels also up-regulate the aromatase promoter, increasing aromatase production in a setting where the substrate, testosterone, levels have increased. In premenopausal women the effect of an aromatase inhibitor results in the increase of total estrogen rather than the intended decrease in its levels. Hence, aromatase inhibitors can only be used for the treatment of post-menopausal women.
Regio-specific conversion of the overproduced estradiol to its carcinogenic (cancer- causing) form by CYP1 B1 , present in high amounts only in pre-cancerous and cancerous cells, is responsible for the onset of breast cancer.
The present invention provides compounds for selectively inhibiting CYP1 B1 for the prevention and treatment of ER-positive breast cancers in both pre- and post-menopausal women. The inventors have recognised that preventing the 'conversion' of overproduced estradiol to the cancer-causing 4-hydroxy estradiol is an attractive way of preventing the onset and progression of majority of breast cancers. Hence, the identification of CYP1 B1 - specific inhibitors provides a novel way of treating the majority (i.e. >80%) of breast cancers. Moreover, proteomic analysis has revealed that CYP1 B1 is over-produced in tumours which have become resistant to chemotherapy with cisplatin. It has been suggested that CYP1 B1 inhibitors would be able to re-sensitise cancer cells to currently available cancer therapies that involve platinum compounds, taxanes and nucleoside analogues. The present invention therefore provides CYP1 B1 inhibitors for use in the treatment of drug-resistant cancer cells, as alternatives to currently used aromatase inhibitors and in gynaecological cancers and prostate cancer.
The present invention therefore provides inhibitors which inhibit CYP1 B1 and more preferably provide selective inhibition of CYP1 B1 .
The first aspect of the invention relates to a compound of formula (I) for use in the prevention and/or treatment of cancer,
wherein each of R1, R2, R3, R4 or R5 are independently selected from hydrogen, aliphatic, alkoxy, thioalkyi, alkylamino, halogen, hydroxy, cyano, nitro, hydroxyalkyi, alkylcarbonyloxy, alkoxycarbonyl, alkylcarbonyl, haloalkyl, alkylsulfonylamino, NH2, N02, S02Rx, SORx and COORx, where Rx is hydrogen, aliphatic or aryl.
In particular, the compounds of formula (I) are provided as selective inhibitors of CYP1 B1.
In particular, each of R1, R2, R3, R4 or R5 are independently selected from hydrogen, aliphatic, halogen, hydroxy, alkoxy, thioalkyi, alkylamino or cyano, preferably hydrogen, hydroxyl, halogen or alkoxy, more preferably hydrogen, hydroxyl or alkoxy.
In a particular, the phenyl ring can be mono-, di- or tri-substituted. Thus, one, two or three of R1, R2, R3, R4 or R5 can be substitued with one or more group independently selected from aliphatic, alkoxy, thioalkyi, alkylamino, halogen, hydroxy, cyano, nitro, hydroxyalkyi, alkylcarbonyloxy, alkoxycarbonyl, alkylcarbonyl, haloalkyl, alkylsulfonylamino, NH2, N02, S02Rx, SORx and COORx, where Rx is hydrogen, aliphatic or aryl.
Preferably one, two or three of R1, R2, R3, R4 or R5 can be substituted with one or more group independently selected from aliphatic, halogen, hydroxy, alkoxy, thioalkyi, alkylamino or cyano, more preferably hydroxyl, halogen or alkoxy, most preferably hydroxyl or alkoxy.
In particular, when R1 and R2 are independently selected from aliphatic, alkoxy, thioalkyi, alkylamino, halogen, hydroxy, cyano, nitro, hydroxyalkyi, alkylcarbonyloxy, alkoxycarbonyl, alkylcarbonyl, haloalkyl, alkylsulfonylamino, NH2, N02, S02Rx, SORx and
COORx, where Rx is hydrogen, aliphatic or aryl, the remaining groups R3, R4 or R5 are hydrogen.
Preferably when R1 and R2 are independently selected from aliphatic, halogen, hydroxy, alkoxy, thioalkyi, alkylamino or cyano, more preferably hydroxyl, halogen or alkoxy, most preferably hydroxyl or alkoxy, the remaining groups R3, R4 or R5 are hydrogen.
Alternatively, when R1, R3, R4 and R5 are hydrogen, R2 is aliphatic, alkoxy, thioalkyi, alkylamino, halogen, hydroxy, cyano, nitro, hydroxyalkyl, alkylcarbonyloxy, alkoxycarbonyl, alkylcarbonyl, haloalkyl, alkylsulfonylamino, NH2, N02, S02Rx, SORx and COORx, where Rx is hydrogen, aliphatic or aryl, preferably aliphatic, halogen, hydroxy, alkoxy, thioalkyi, alkylamino or cyano, more preferably hydroxyl, halogen or alkoxy, most preferably hydroxyl or alkoxy.
When R1, R2 and R3 are aliphatic, alkoxy, thioalkyi, alkylamino, halogen, hydroxy, cyano, nitro, hydroxyalkyl, alkylcarbonyloxy, alkoxycarbonyl, alkylcarbonyl, haloalkyl, alkylsulfonylamino, NH2, N02, S02Rx, SORx and COORx, where Rx is hydrogen, aliphatic or aryl, preferably aliphatic, halogen, hydroxy, alkoxy, thioalkyi, alkylamino or cyano, more preferably hydroxyl, halogen or alkoxy, most preferably hydroxyl or alkoxy, R4 and R5 are hydrogen.
Alternatively, when R1, R2, R4 and R5 are hydrogen, R3 is aliphatic, alkoxy, thioalkyi, alkylamino, halogen, hydroxy, cyano, nitro, hydroxyalkyl, alkylcarbonyloxy, alkoxycarbonyl, alkylcarbonyl, haloalkyl, alkylsulfonylamino, NH2, N02, S02Rx, SORx and COORx, where Rx is hydrogen, aliphatic or aryl, preferably, aliphatic, halogen, hydroxy, alkoxy, thioalkyi, alkylamino or cyano, more preferably hydroxyl, halogen or alkoxy, most preferably hydroxyl or alkoxy. When R2, R3 and R4 are aliphatic, alkoxy, thioalkyi, alkylamino, halogen, hydroxy, cyano, nitro, hydroxyalkyl, alkylcarbonyloxy, alkoxycarbonyl, alkylcarbonyl, haloalkyl, alkylsulfonylamino NH2, N02, S02Rx, SORx and COORx, where Rx is hydrogen, aliphatic or aryl, preferably, aliphatic, halogen, hydroxy, alkoxy, thioalkyi, alkylamino or cyano,
more preferably hydroxyl, halogen or alkoxy, most preferably hydroxyl or alkoxy, R1 and R5 are hydrogen.
In a particular feature of the first aspect of the invention, each of R1, R2, R3, R4 or R5 are independently hydrogen, hydroxyl or alkoxy, preferably methoxy.
To this end, preferred compounds of the first aspect of the invention, are those in which the phenyl ring can be mono-, di- or tri-substituted with hydroxyl or alkoxy, preferably alkoxy. In particular, when R3, R4 and R5 are hydrogen and R1 is alkoxy, R2 can be hydrogen or alkoxy. When R2 is alkoxy, R4 and R5 are hydrogen, R1 and R3 can be hydrogen or alkoxy. When R3 is alkoxy and R1 and R5 are hydrogen, R2 and R4 can be hydrogen or alkoxy.
Preferably when R3, R4 and R5 are hydrogen, R1 and R2 are alkoxy or hydroxyl, preferably alkoxy.
To this end, preferred compounds of the first aspect of the invention, are those in which the phenyl ring can be mono-, di- or tri-substituted with hydroxyl or methoxy, preferably methoxy. In particular, when R3, R4 and R5 are hydrogen and R1 is methoxy, R2 can be hydrogen or methoxy. When R2 is methoxy, R4 and R5 are hydrogen, R1 and R3 can be hydrogen or methoxy. When R3 is methoxy and R1 and R5 are hydrogen, R2 and R4 can be hydrogen or methoxy.
Preferably when R3, R4 and R5 are hydrogen, R1 and R2 are methoxy or hydroxyl, preferably methoxy.
As discussed above, the compounds of formula (I) are provided as selective inhibitors of CYP1 B1. For the purposes of the present invention, the term aryl includes for example optionally substituted unsaturated monocyclic, bicyclic or tricyclic rings of up to 14 carbon atoms, such as phenyl, naphthy and phenanthroline. Alternatively, the term aryl may include partially saturated bicyclic rings such as tetrahydro-naphthyl. Preferably, the aryl group is phenyl, naphthy or phenanthroline.
The term "aliphatic" as used herein refers to a straight or branched chain hydrocarbon which is completely saturated or contains one or more units of unsaturation. Thus, aliphatic may be alkyl, alkenyl or alkynyl, preferably having 1 to 12 carbon atoms, up to 6 carbon atoms or up to 4 carbon atoms.
For the purposes of this invention, alkyl relates to both straight chain and branched alkyl radicals of 1 to 12 carbon atoms, preferably 1 to 8 carbon atoms and most preferably 1 to 4 carbon atoms including but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, sec- butyl, isobutyl, tert-butyl n-pentyl, n-hexyl, n-heptyl, n-octyl. The term alkyl therefore relates to radicals comprising 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 or 12 carbon atoms. The term alkyl also encompasses cycloalkyl radicals of 3 to 12 carbon atoms, preferably 4 to 8 carbon atoms, and most preferably 5 to 6 carbon atoms including but not limited to cyclopropyl, cyclobutyl, CH2-cyclopropyl, CH2-cyclobutyl, cyclopentyl or cyclohexyl. Cycloalkyl groups may be optionally substituted or fused to one or more carbocyclyl or heterocyclyl group. Haloalkyl relates to an alkyl radical preferably having 1 to 8 carbon atoms, preferably 1 to 4 carbon atoms substituted with one or more halide atoms for example CH2CH2Br, CF3 or CCI3. The term "alkenyl" means a straight chain or branched alkylenyl radical of 2 to 12 carbon atoms, preferably 2 to 6 carbon atoms and most preferably 2 to 4 carbon atoms, and containing one or more carbon-carbon double bonds and includes but is not limited to ethylene, n-propyl-1 -ene, n-propyl-2-ene, isopropylene, etc.. The term "alkynyl" means a straight chain or branched alkynyl radical of 2 to 12 carbon atoms, preferably 2 to 6 carbon atoms and most preferably 2 to 4 carbon atoms, and containing one or more carbon-carbon triple bonds and includes but is not limited to ethynyl, 2-methylethynyl etc. The term alkenyl and alkynyl therefore encompass radicals comprising 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 or 12 carbon atoms. The term "alkoxy" as used herein refers to an oxy group that is bonded to an alkyl group as defined herein. An alkoxy is preferably a "C1-8 alkoxy group", even more preferably a "Ci-6 alkoxy group" and more preferably a "C1-4 alkoxy group". The alkoxy group particularly includes 1 , 2, 3 or 4 carbon atoms. Particularly preferably alkoxy groups include methoxy, ethoxy, propyloxy or butyloxy.
Halogen means F, CI, Br or I, preferably F.
Preferred compounds of the invention listed above extend to the tautomers thereof, as well as (but not limited to) pharmaceutically acceptable salts, esters, amides, carbamates, carbonates, ureides or prodrugs thereof or a derivative optionally with one or more lipid groups (natural or synthetic) attached.
The invention extends to prodrugs of the aforementioned compounds. A prodrug is any compound that may be converted under physiological conditions or by solvolysis to any of the compounds of the invention or to a pharmaceutically acceptable salt of the compounds of the invention. A prodrug may be inactive when administered to a subject but is converted in vivo to an active compound of the invention.
The compounds of the invention may contain one or more stereogenic (asymmetric) carbon atoms and may exist in racemic and optically active forms (enantiomers or diastereoisomers). The first aspect of the invention includes all such enantiomers or diastereoisomers and mixtures thereof, including racemic mixtures.
Examples of pharmaceutically acceptable salts of the compounds of formulae (I) include those derived from organic acids such as methanesulphonic acid, benzenesulphonic acid and p-toluenesulphonic acid, mineral acids such as hydrochloric and sulphuric acid and the like, giving methanesulphonate, benzenesulphonate, p-toluenesulphonate, hydrochloride and sulphate, and the like, respectively or those derived from bases such as organic and inorganic bases. Examples of suitable inorganic bases for the formation of salts of compounds for this invention include the hydroxides, carbonates, and bicarbonates of ammonia, lithium, sodium, calcium, potassium, aluminium, iron, magnesium, zinc and the like. Salts can also be formed with suitable organic bases. Such bases suitable for the formation of pharmaceutically acceptable base addition salts with compounds of the present invention include organic bases which are nontoxic and strong enough to form salts. Such organic bases are already well known in the art and may include amino acids such as arginine and lysine, mono-, di-, or trihydroxyalkylamines such as mono-, di-, and triethanolamine, choline, mono-, di-, and trialkylamines, such as methylamine, dimethylamine, and trimethylamine, guanidine; N-methylglucosamine; N- methylpiperazine; morpholine; ethylenediamine; N-benzylphenethylamine; tris(hydroxymethyl) aminomethane; and the like. Salts may be prepared in a conventional manner using methods well known in the art. Acid addition salts of said basic compounds may be prepared by dissolving the free base compounds according to the first or second aspects of the invention in aqueous or aqueous alcohol solution or other suitable solvents containing the required acid. Where a compound of formula (I) contain an acidic function a base salt of said compound may be
prepared by reacting said compound with a suitable base. The acid or base salt may separate directly or can be obtained by concentrating the solution eg. by evaporation. The compounds of this invention may also exist in solvated or hydrated forms. The compounds of the invention are provided for the prevention and/or treatment of cancer. As discussed above, conventional aromatase inhibitors can not be used in premenopausal women as they result in an increase in total estrogen rather than the intended decrease. The provision of inhibitors which selectively inhibit CYP1 B1 allows the treatment of hormone-induced cancers (such as breast, ovarian, uterine, endometrial and prostate cancer). In particular, the claimed invention provides a compound for use in the prevention and/or treatment of hormone induced cancers in both pre- and postmenopausal women.
The compound of formula (I) as described above is therefore provided for the prevention and/or treatment of hormone-induced cancers, preferably breast, ovarian, uterine, endometrial and prostate cancer. The compounds of formula (I) are further provided for the prevention and/or treatment of hormone-induced cancers, preferably breast, ovarian, uterine, endometrial and prostate cancer in pre- and/or post-menopausal women, preferably pre-menopausal women.
Throughout this text, the prevention and/or treatment of cancer means any effect which mitigates any damage, to any extent. The term "treatment" means any amelioration of disorder, disease, syndrome, condition, pain or a combination of two or more thereof. The term prevention means to prevent the condition from occurring, lessening the severity of the condition or to prevent from deteriorating or getting worse for example by halting the progress of the disease without necessary ameliorating the condition.
The present invention particularly relates to the treatment of cancer. The second aspect of the invention relates to novel compounds of formula (I)
wherein each of R1, R2, R3, R4 or R5 are independently hydrogen, or methoxy.
In particular, the compounds of formula (I) are provided as selective inhibitors of CYP1 B1. To this end, preferred compounds of the first aspect of the invention are those in which the phenyl ring can be mono-, di- or tri-substituted with hydroxyl or methoxy, preferably methoxy. In particular, when R3, R4 and R5 are hydrogen and R1 is methoxy, R2 can be hydrogen or methoxy. When R2 is methoxy and R4 and R5 are hydrogen, R1 and R3 can be hydrogen or methoxy. When R3 is methoxy and R1 and R5 are hydrogen, R2 and R4 can be hydrogen or methoxy.
Preferably when R3 and R4 and R5 are hydrogen, R1 and R2 are methoxy or hydroxyl, preferably methoxy.
In particular, the compound is one or more selected from
A third aspect of the invention provides a composition comprising a compound, in particular a novel compound according to the first or second aspects of the invention, in combination with a pharmaceutically acceptable excipient. The pharmaceutically acceptable excipient may comprise a pharmaceutically acceptable carrier and/or pharmaceutically acceptable diluent. Suitable carriers and/or diluents are well known in
the art and include pharmaceutical grade starch, mannitol, lactose, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, (or other sugar), magnesium carbonate, gelatin, oil, alcohol, detergents, emulsifiers or water (preferably sterile). The composition may be a mixed preparation of a composition or may be a combined preparation for simultaneous, separate or sequential use (including administration).
A pharmaceutical composition may be provided in unit dosage form, will generally be provided in a sealed container and may be provided as part of a kit. Such a kit would normally (although not necessarily) include instructions for use. It may include a plurality of said unit dosage forms.
The compounds according to the invention for use in the aforementioned indications may be administered by any convenient method, for example by oral (including by inhalation), parenteral, mucosal (e.g. buccal, sublingual, nasal), rectal or transdermal administration and the compositions adapted accordingly. Such compositions may be prepared by any method known in the art of pharmacy, for example by admixing the active ingredient with a carrier(s) or excipient(s) under sterile conditions.
For oral administration, the compounds can be formulated as liquids or solids, for example solutions, syrups, suspensions or emulsions, tablets, capsules and lozenges. Pharmaceutical compositions adapted for oral administration may be presented as discrete units such as capsules or tablets; as powders or granules; as solutions, syrups or suspensions (in aqueous or non-aqueous liquids; or as edible foams or whips; or as emulsions). Suitable excipients for tablets or hard gelatine capsules include lactose, starch including maize starch or derivatives thereof, stearic acid or salts thereof, such as magnesium stearate, sucrose or microcrystalline cellulose. A composition in the form of a capsule can be prepared using routine encapsulation procedures. For example, powders, granules or pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule. Suitable excipients for use with soft gelatine capsules include for example vegetable oils, waxes, fats, semi-solid, or liquid polyols etc.
Compositions for oral administration may be designed to protect the active ingredient against degradation as it passes through the alimentary tract, for example by an outer coating of the formulation on a tablet or capsule. A liquid formulation, such as a solution or a syrup will generally consist of a suspension or solution of the compound or physiologically acceptable salt in a suitable aqueous or nonaqueous liquid carrier(s) for example water, ethanol, glycerine, sugars, polyethylene glycol or an oil. For the preparation of suspensions oils (e.g. vegetable oils) may be used to provide oil-in-water or water in oil suspensions. The formulation may also contain a suspending agent, preservative, flavouring or colouring agent.
Compositions for nasal or oral administration may conveniently be formulated as aerosols, drops, gels and powders. Aerosol formulations typically comprise a solution or fine suspension of the active substance in a physiologically acceptable aqueous or non- aqueous solvent and are usually presented in single or multidose quantities in sterile form in a sealed container, which can take the form of a cartridge or refill for use with an atomising device. Alternatively the sealed container may be a unitary dispensing device such as a single dose nasal inhaler or an aerosol dispenser fitted with a metering valve which is intended for disposal once the contents of the container have been exhausted. Where the dosage form comprises an aerosol dispenser, it will contain a pharmaceutically acceptable propellant. The aerosol dosage forms can also take the form of a pump- atomiser.
Pharmaceutical compositions adapted for nasal administration wherein the carrier is a solid include a coarse powder having a particle size for example in the range 20 to 500 microns which is administered in the manner in which snuff is taken, i.e. by rapid inhalation through the nasal passage from a container of the powder held close up to the nose. Suitable compositions wherein the carrier is a liquid, for administration as a nasal spray or as nasal drops, include aqueous or oil solutions of the active ingredient.
Pharmaceutical compositions adapted for topical administration may be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils. For application to the eye or other external tissues, for example mouth and skin, the compositions are preferably applied as a topical ointment or cream. When formulated in an
ointment, the active ingredient may be employed with either a paraffinic or a water-miscible ointment base. Alternatively, the active ingredient may be formulated in a cream with an oil- in-water cream base or a water-in-oil base. Pharmaceutical compositions adapted for topical administration to the eye include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent. Pharmaceutical compositions adapted for topical administration in the mouth include lozenges, pastilles and mouth washes. Pharmaceutical compositions adapted for rectal administration may be presented as suppositories or enemas. Pharmaceutical compositions adapted for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations. Compositions for rectal or vaginal administration are conveniently in the form of suppositories (containing a conventional suppository base such as cocoa butter), pessaries, vaginal tabs, foams or enemas.
Compositions suitable for buccal or sublingual administration include tablets, lozenges and pastilles, wherein the active ingredient is formulated with a carrier such as sugar and acacia, tragacanth, or gelatin and glycerin.
Compositions suitable for transdermal administration include ointments, gels, patches and injections including powder injections.
Conveniently the composition is in unit dose form such as a tablet, capsule or ampoule. Pharmaceutical compositions adapted for parenteral administration include aqueous and non-aqueous sterile injection solution which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation substantially isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. Excipients which may be used for injectable solutions include water, alcohols, polyols, glycerine and vegetable oils, for example. The compositions may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carried, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets.
The pharmaceutical compositions may contain preserving agents, solubilising agents, stabilising agents, wetting agents, emulsifiers, sweeteners, colourants, odourants, salts, buffers, coating agents or antioxidants. They may also contain an adjuvant and/or therapeutically active agents in addition to the substance of the present invention.
Dosages of the substance of the present invention can vary between wide limits, depending upon a variety of factors including the disease or disorder to be treated, the age, weight and condition of the individual to be treated, the route of administration etc. and a physician will ultimately determine appropriate dosages to be used. Typically, however, the dosage adopted for each route of administration when a compound of the invention is administered to adult humans is 0.001 to 500 mg/kg. Such a dosage may be given, for example, from 1 to 5 times daily by bolus infusion, infusion over several hours and/or repeated administration. The compositions may be administered in conjunction with one or more other therapeutically active agents, especially those effective for treating cancers (i.e. a chemotherapeutic agent). Another chemotherapeutic agent may be, for example, mitoxantrone, Vinca alkaloids, such as vincristine and vinblastine, anthracycline antibiotics such as daunorubicin and doxorubicin, alkylating agents such as chlorambucil and melphalan, taxanes such as paclitaxel, anti-folates such as methotrexate and tomudex, epipodophyllotoxins such as etoposide, camptothecins such as irinotecan and its active metabolite SN-38 and DNA methylation inhibitors. The other active compound(s) may be incorporated in the same composition as the compounds of the present invention or they may be administered alongside the compounds of the present invention, e.g. simultaneously or sequentially. Thus, the invention provides a kit of parts comprising a compound of the invention and another chemotherapeutic agent, optionally with instructions for use.
Alternatively, the compound of the first or second aspects of the invention may be administered by their addition to a food or drink. In an alternative feature of the third aspect of the invention, the compounds of the first or second aspects of the invention are formulated into a powder or liquid for addition to food or drink and administration by these means. In this feature of the third aspect, the compounds of the first or second aspects will be formulated with an excipient or diluent but such excipient or diluent does not need to be pharmaceutically acceptable but instead should be acceptable for consumption.
A fourth aspect of the invention provides a process for the manufacture of a composition according to the third aspect of the invention. The manufacture can be carried out by standard techniques well known in the art and involves combining a compound according to the first or second aspect of the invention and a pharmaceutically acceptable carrier or diluent. The composition may be in any form including a tablet, a liquid, a capsule, and a powder or in the form of a food product, e.g. a functional food. In the latter case the food product itself may act as the pharmaceutically acceptable carrier.
The fifth aspect of the invention provides a method of preventing and/or treating cancer comprising administering a compound of the first or second aspects of the invention to a patient in need thereof.
The method is particularly provided for the prevention and/or treatment of hormone- induced cancers, preferably breast, ovarian, uterine, endometrial and prostate cancer. The compounds of formula (I) are further provided for the prevention and/or treatment of hormone-induced cancers, preferably breast, ovarian, uterine, endometrial and prostate cancer in pre- and/or post-menopausal women, preferably pre-menopausal women.
As discussed above, the compounds of the present invention inhibit the conversion of pre- carcinogens into carcinogenic compounds thereby reducing or removing the risk of cancer. The patient in need thereof does not therefore need to be suffering from cancer but can instead wish to reduce his or her risk of cancer.
Thus the fifth aspect of the invention provides a method of reducing the risk of developing cancer, comprising administering a compound of the first or second aspects of the invention. A person wishing to reduce this or her risk of cancer may be a person who is genetically predisposed to cancer or who is at risk of cancer due to environmental factors (i.e. smoking, pollution, exposure to toxins etc.). The compound of the first aspect of the invention can be provided in combination with one or more other therapeutic agents, especially those effective for treating cancers (i.e. a chemotherapeutic agent) as described in the third aspect of the invention.
The sixth aspect of the invention relates to the use of the compounds of the first or second aspects of the invention in the manufacture of a medicament for the prevention and/or treatment of cancer. As discussed above, the compounds of the present invention inhibit the conversion of pre- carcinogens into carcinogenic compounds thereby reducing or removing the risk of cancer. The medicament can therefore be provided to patient who is not suffering from cancer but instead wishes to reduce his or her risk of cancer. The compounds of the first or second aspects of the invention can be provided in combination with one or more other therapeutic agents, especially those effective from treating cancers (i.e. a chemotherapeutic agent) as described in the third aspect of the invention. The seventh aspect of the invention relates to a composition comprising a compound of formula (I) as defined in the first and second aspects of the invention and a drug for treating cancer.
The drug for treating cancer is one or more selected from mitoxantrone, Vinca alkaloids, such as vincristine and vinblastine, anthracycline antibiotics such as daunorubicin and doxorubicin, alkylating agents such as chlorambucil and melphalan, taxanes such as paclitaxel, anti-folates such as methotrexate and tomudex, epipodophyllotoxins such as etoposide, camptothecins such as irinotecan and its active metabolite SN-38 and DNA methylation inhibitors.
Preferably the drug for treating cancer is one or more of a platinum compound, such as cisplatin, a taxane or a nucleoside analogue.
The compound of formula (I) acts to re-sensitise cancer cells which are resistant to currently available cancer therapies. The eighth aspect of the invention therefore relates to a composition comprising a compound of formula (I) as defined in the first and second aspects of the invention and a drug for treating cancer for use in treating cancer, wherein the cancer is resistant to the cancer treating drug.
For the purposes of this invention, the term "resistant" indicates that the cancer therapy either has a decreased effect or no effect on the cancer cells.
All preferred features of the first to fifth aspects of the invention relate to all other aspects of the invention mutandis mutandi. In particular, cancer according to the fourth and fifth aspects of the invention is as defined in the first aspect of the invention.
Description of figures. Figure 1 illustrates the plasmid map of pcDNA3.1/h_CYP1 B1.
Figure 2. illustrates confirmation of the presence of CYP1 B1 protein in HEK293 and CHO- K1 cells transfected with pcDNA3.1/h_CYP1 B1 by western blotting; and Figure 3. illustrates confirmation of the presence of CYP1 B1 protein in A2780 and A2780cis cells by western blotting. 1.74 μg of protein for A2780 and 0.3 μg of protein for A2780cis cells were fractionated by 10% SDS-PAGE followed by immunoblotting.
Examples
Methods for synthesis of stilbene derivatives Synthesized Stilbene derivatives
Lithium hydroxide (21 mg, 0.5mmol) was added to solution of 3-pyridylacetonitrile (0.54ml, 5.09mmol) in ethanol (5ml). The mixture was stirred at room temperature for 10 minutes before addition of the benzaldehyde (5.09mmol). The reaction was stirred overnight resulting in the formation of a coloured precipitate. The mixture was quenched with water (50 ml) and extracted with ethyl acetate (3 x 30ml). The combined organic extracts were washed with saturated brine, dried with anhydrous magnesium sulphate and the solvent removed in vacuo. The crude product was purified by column chromatography using hexane (15%): ethyl acetate (80%): triethylamine (5%) as eluent.
Chemical structure and physical properties of synthesised stilbenes
Brown fluffy powder (889mg, 65%), TLC: Rf 0.65 (ethyl acetate/hexane/ triethylamine 6:3.5:0.5); m.p. (83-85°C); m/z [FAB+] 297.1236 ([M+H]+, 100%); Ymax (KBr)/cm"1 1574 (C=N), δΗ (CDCIs): 3.90 (3H, s, OCH3), 3.98 (3H, s, OCH3), 4.10 (3H, s, OCH3), 6.89 (2H, s, ArH), 7.98 (1 H, d, C=CH), 7.76 (1 H, d, PyH), 8.10 (1 H, t, PyH), 8.78 (1 H, d, PyH), 9.10 (1 H, d, PyH), 5c (CDCI3): 55.3, 56.6, 60.1 , 109.6, 1 10.3, 1 19.9, 122.3, 124.6, 144.3, 149.7, 151.7, 156.4 HRMS found [M+H]+ 297.1236, Ci7H1703N2 requires [M+H]+ 297.1239. 2. DMU-SB2
Light brown fluffy powder (890mg, 65%), TLC: Rf 0.65 (ethyl acetate/hexane/ triethylamine 6:3.5:0.5); m.p. (83-85°C); m/z [FAB+] 297.1236 ([M+H]+, 100%); Ymax (KBr)/cm"1 1591 (C=N), δΗ (CDCI3): 3.90 (3H, s, OCH3), 3.98 (3H, s, OCH3), 4.10 (3H, s, OCH3), 6.89 (2H, d, ArH), 7.98 (1 H, s, C=CH), 7.76 (1 H, dd, PyH), 8.10 (1 H, d, PyH), 8.78 (1 H, d, PyH), 9.10 (1 H, d, PyH), 5C (CDCI3): 55.3, 56.6, 60.1 , 109.6, 1 10.3, 1 19.9, 122.3, 124.6, 144.3, 149.7, 151.7, 156.4 HRMS found [M+H]+ 297.1235, C17H1703N2 requires [M+H]+ 297.1234. 3. DMU-SB3
Cream colour powder (880mg, 73%), TLC: Rf 0.65 (ethyl acetate/hexane/ triethylamine 6:3.5:0.5); m.p. (87-89°C); m/z [FAB+] 237.1023 ([M+H]+, 100%); Ymax (KBr)/cm"1 1598 (C=N), δΗ (CDCIs): 3.98 (3H, s, OCH3), 6.92 (1 H, d, ArH), 6.98 (1 H, d, ArH), 7.09 (2H, s, ArH), 7.98 (1 H, s, C=CH), 8.10 (1 H, d, PyH), 8.78 (1 H, dd, PyH), 8.86 (1 H, d, PyH), 9.10 (1 H, d, PyH), 5c (CDCI3): 55.3, 109.6, 1 10.3, 1 19.9, 122.3, 124.6, 144.3, 149.7, 151.7, 156.4, 160.2 HRMS found [M+H]+ 237.1023, Ci5H1302N2 requires [M+H]+ 237.1022.
4. DMU-SB4
Pale yellow colour powder (886mg, 73%), TLC: Rf 0.65 (ethyl acetate/hexane/ triethylamine 6:3.5:0.5); m.p. (85-87°C); m/z [FAB+] 237.1018 ([M+H]+, 100%); Ymax (KBr)/cm"1 1604 (C=N), δΗ (CDCI3): 3.98 (3H, s, OCH3), 6.92 (2H, d, ArH), 6.98 (2H, dd, ArH), 7.98 (1 H, d, C=CH), 8.10 (1 H, dd, PyH), 8.78 (1 H, d, PyH), 8.86 (1 H, d, PyH), 9.10 (1 H, d, PyH), 5c (CDCI3): 55.3, 109.6, 1 10.3, 1 19.9, 122.3, 124.6, 130.2, 144.3, 149.7, 151.7, 156.4, 160.1 HRMS found [M+H]+ 237.1018, Ci5H130iN2 requires [M+H]+ 237.1022.
5. DMU-SB5
Cream colour powder (884mg, 65%), TLC: Rf 0.65 (ethyl acetate/hexane/ triethylamine 6:3.5:0.5); m.p. (1 10-1 15°C); m/z [FAB+] 267.1 131 ([M+H]+, 100%); Ymax (KBr)/cm"1 1592 (C=N), δΗ (CDCI3): 3.90 (3H, s, OCH3), 4.10 (3H, s, OCH3), 6.97 (2H, dd, ArH), 7.34 (1 H, d, ArH), 7.98 (1 H, s, C=CH), 8.68 (1 H, dd, PyH), 8.78 (1 H, d, PyH), 8.99 (1 H, d, PyH), 9.10 (1 H, d, PyH), 5C (CDCI3): 55.3, 56.6, 109.6, 1 10.3, 1 19.9, 122.3, 124.6, 135.2, 144.3, 149.7, 151.7, 156.4 HRMS found [M+H]+ 267.1 131 , C16H1502N2 requires [M+H]+ 267.1 128.
6. DMU-SB6
White fluppy powder (940mg, 69%), TLC: Rf 0.65 (ethyl acetate/hexane/ triethylamine 6:3.5:0.5); m.p. (107-1 10°C); m/z [FAB+] 267.1 125 ([M+H]+, 100%); ymax (KBr)/cm"1 1567 (C=N), δΗ (CDCIs): 3.90 (3H, s, OCH3), 4.10 (3H, s, OCH3), 7.10 (1 H, d, ArH), 7.34-7.44 (2H, M, ArH), 7.98 (1 H, s, C=CH), 8.68 (1 H, d, PyH), 8.78 (1 H, dd, PyH), 8.99 (1 H, d, PyH), 9.10 (1 H, d, PyH), 5C (CDCI3): 55.3, 56.6, 109.6, 1 10.3, 1 19.9, 122.3, 124.6, 135.1 , 140.1 , 144.3, 149.7, 151 .7, 156.4 HRMS found [M+H]+ 267.1 125, Ci6H1502N2 requires [M+H]+ 267.1 128.
7. DMU-SB7
Pale yellow powder (920mg, 88%), TLC: Rf 0.65 (ethyl acetate/hexane/ triethylamine 6:3.5:0.5); m.p. (107-1 10°C); m/z [FAB+] 206.1 105 ([M+H]+, 100%); vmax (KBrycrrf1 1566 (C=N), δΗ (CDCIs): 7.10 (1 H, d, ArH), 7.44 (2H, M, ArH), 7.76 (1 H, d, ArH), 7.98 (1 H, d, C=CH), 8.10 (1 H, d, PyH), 8.67 (1 H, d, PyH), 8.86 (1 H, dd, PyH), 8.98 (1 H, d, PyH), 5C (CDCIs): 109.6, 1 10.3, 1 19.9, 122.3, 124.6, 130.2, 135.3, 144.3, 149.7, 151.7, 156.4 HRMS found [M+H]+ 206.1 1 10, Ci3H10N2 requires [M+H]+ 206.1 1 10. Example 1. Determination of IC50 values
This method is used to measure the IC50 values (the concentration at which 50 % of the enzyme activity is inhibited) of the compounds. IC50 values, which effectively reflect the inhibitory potential of a compound, provides evidence of the possible effectiveness of a compound in a biological process.
An IC50 assay includes microsomes which either contain cytochrome P450 enzymes, a chosen chemical compound in six serial dilutions, DMSO, 96-well flat-bottomed microtitre
plate, substrates such as ER or CEC or EOMCC or DBF (which form fluorescent compounds upon CYP metabolism) and a fluorescent plate reader which ultimately determines IC50 values via endpoint fluorescence assays. CYP1 B1 End Point Assay
Regenerating System consists of:
5 μΙ Solution A (183 mg of NADP+ + 183 mg of glucose-6-phosphate + 654 μΙ of 1.0 M magnesium chloride solution + 9.15 ml of sterile ultra-pure water) + 1 μΙ Solution B (250 Units of glucose-6-phosphate dehydrogenase + 6.25 ml of 5 mM sodium citrate, mixed in a tube and made up to 10 ml with sterile ultra-pure water) + 39 μΙ 0.2 M Kpi (0.6 ml of 1.0M K2HP04 + 9.4 ml of 1.0M KH2P04 were mixed and made up to 50 ml with sterile ultra-pure water) + 5 μΙ potential inhibitory compound.
Enzyme System consists of:
0.5 μΙ CYP1 B1 (0.5 pmoles; CYP Design Ltd) + 1 .7 μΙ control protein (denatured proteins from yeast cells that do not contain recombinant CYP450 proteins) + 5 μΙ 0.1 mM 7-ER (7- ethoxyresorufin substrate) + 42.8 μΙ 0.1 M Kpi (0.3 ml of 1.0 M K2HP04 + 4.7 ml of 1.0 M KH2P04 were mixed and made up to 50 ml with sterile ultra-pure water).
The Assay is performed using (a) Sensitivity (Gain): 65/70/75 of the Biotek Synergy plate reader (this would differ from one instrument to the other) and (b) Filters: 530/590 nm that monitors fluorescence excitation/ emission.
Procedure for IC50 determination
The computer was switched on and the KC4 software (on the BioTek plate reader) was opened to select the assay parameters and plate layout. The plate reader machine was warmed at 37°C. Compounds were serially diluted to six different concentrations with 10% DMSO in a Sero-Wel white microplate. Serial dilutions were made with a dilution factor of 1 :20. 45 μΙ of regenerating system was prepared and pre-warmed at 37°C as detailed in (Table 2). Meanwhile, 50 μΙ of enzyme substrate mix reaction was prepared and kept for incubation at 37°C for 10 minutes (Table 3). In wells of a 96-well flat-bottomed microplate, 45 μΙ of regenerating system, 5 μΙ serial dilutions of inhibitor were added from the dilution plate and 50 μΙ of enzyme/substrate was added except in control well (positive control); for this well, instead of inhibitor 5 μΙ of 10% DMSO was added. In the background well
(negative control), only 45 μΙ regenerating system and 5 μΙ 10% DMSO were added but no enzyme and then microplate was vortexed for few seconds. The microplate was incubated for 10 minutes. After 10 minutes, 75 μΙ of Tris-acetonitrile was added to all wells using an 8-channel multi-pipette to stop the reaction; after that 50 μΙ of enzyme/substrate reaction was added into the background well. The plate was left to shake for 10 seconds and an endpoint assay was run using appropriate settings.
Calculation of IC50 values
• Step 1 : Calculated percentage inhibition of the samples
· Step 2: Subtracted the value below 50% by 50 = A
• Step 3: Chose the value above 50% and below 50% and subtract the values = B
• Step 4: Divided A by B = C
• Step 5: Multiplied C by ( high concentration obtained - minus lower concentration obtained) = D
· Step 6: Added lower concentration than D which probably will lead to IC50 value
• Step 7: IC50 = (50- low percentage below 50%) x (higher concentration - lower concentration) + lower concentration.
Example 2. The IC50s of potent inhibitors of CYP1 B1 based on their percentage inhibition
The IC50s were determined using the CYP1 B1 endpoint protocol. The IC50 graphs were produced using GraphPad Prism 6 and the structures of compounds were drawn using Symyx Draw. The compounds are grouped together on the basis of their structural similarities. In the graphs shown in Table 1 , effects of an inhibitor on EROD activity catalysed by CYP1 B1 are shown. All assays included the substrate 7-ER in the presence of indicated concentrations of the inhibitor. Each point represents the mean of triplicate readings; bars denote ± SD. The axis represents the logarithmic values of the concentration of inhibitor in μΜ.
Table 1 : Structures and IC50 graphs of compounds that inhibit CYP1 B1 assay.
Stilbenes
The assays provide a rapid and inexpensive method of determining the inhibitory potential of compounds. The assays could also be used to determine the expression levels of a particular CYP from different clones. The cells can be grown and expressed at various time points and the metabolism of a fluorescence substrate can be analysed to determine the relative amounts of a CYP that is produced from different clones.
The cell-based enzyme inhibition assays were carried out to find if the earlier results obtained from the in vitro enzyme assays (using isolated microsomes) have any bearing in the cellular context. This can be achieved by comparing results from the in vitro assays with those obtained from cellular assays. As observed with microsomes, P450 activity is inhibited by certain compounds. However, it is important to consider if live cells expressing CYP1A1 , CYP1 B1 and CYP1A2 enzymes have the potential to take up the compounds of interest through the yeast cell wall.
Recombinant yeast cells that harbour the CYP1A1, CYP1B1 and CYP1A2 genes and are activated by a reductase, AhRDM, were grown. Assays were carried out using selected compounds which had already shown specificity towards microsomal CYP1A1 , CYP1 B1 and CYP1A2 enzymes during in vitro IC50 determinations of these compounds.
The live cell procedures include the use of 96-well flat-bottomed microplates, the substrates and a multi-mode filter plate reader to obtain fluorescence outputs that help in determining IC50 values. Procedure for live cell assays
From frozen glycerol stocks yeast strains were streaked out for growth on SD-minimal medium agar plates that contained the required nutrients and 2% glucose. The plates were then incubated at 30°C for 3 days. A loop-full of cells, from one of the many colonies that grew on the SD-minimal medium agar plate, were taken and were inoculated in 10 ml of autoclaved minimal medium broth that contained 0.02% casamino acids (SW6 broth) in a sterile conical flask. The broth was incubated in a shaking incubator at 30°C at 220 rpm for 16 hours. The culture was then diluted 1 :10 and optical density was measured at 600 nm. Once the optical density of SW6 broth culture reached OD600 between 5 and 6, 10 ml of SW6 pre-culture was transferred to a sterile 10 ml tube and centrifuged at 3000 g for 10
minutes, the pellet obtained was transferred to a sterile conical flask containing 10 ml of SE medium which contained yeast nitrogen base, 2% ethanol, 12.5 ml/litre L-adenine, 8.3 ml/litre of L-histidine, L-leucine, and L-tryptophan. 10 ml of cell culture was incubated at 30°C at 220 rpm for 4 hours. After 4 hours, approximately 0.4 X 107 cells per ml were aliquoted into sterile Eppendorf tubes and centrifuged at 13,000 rpm. The supernatant was poured off and cell pellet was washed with TE buffer 3 times. Finally, the cell pellet was re-suspended in 450 μΙ of TE buffer (0.5M Tris-HCI, pH7.4 and 0.1 M EDTA). Meanwhile, serial dilutions of selected compounds were made to yield different concentrations of compound. In each well of black microplate, 50 μΙ of cell suspension (containing a specific CYP), 5 μΙ of potential inhibitor (selected chemical compounds) and 50 μΙ of substrate mixture (containing CYP-specific substrates) were added. In the control wells, 45μΙ of cell suspension (contain a specific CYP) was mixed with 5 μΙ 10% DMSO and 50μΙ of CYP-specific substrate. After preparation of all wells, the microplate was vortexed for 10 seconds so that contents were mixed well in each well and kinetic assay was carried out for 30 minutes at 30°C using appropriate settings (see Table 2).
Table 2: Outline of kinetic assay parameters used for analysing cytochrome P450 enzymes using live cells and the Bio-Tek Synergy HT fluorescent plate reader.
Example s IC50 values in CYP1 B1 , CYP1A1 , CYP1A2, CYP2D6 and CYP3A4 enzyme (in vitro) and live cell assays (using CYP1A1 , CYP1 B1 and CYP1A2 yeast microsomes and recombinant cells)
5 Table 3.
Example 5. Re-sensitization of recombinant HEK-293 cells carrying the CYP1 B1 gene to cisplatin and paclitaxel
CYP1 B1 is expressed in high amounts in tissues which overproduce oestrogen, tissues like the breast, uterus and ovaries. Overproduction of oestrogen causes the perpetual activation of the oestrogen receptor ultimately leading to tumour formation.
Experimental studies have also suggested that CYP1 B1 may offer a mechanism of anticancer drug resistance. Hence inhibition of CYP1 B1 by CYP1 B1 -specific inhibitors 15 may offer a novel mechanism for overcoming drug resistance in some form of cancers.
A cell line which overproduces CYP1 B1 was created to confirm that CYP1 B1 overproduction indeed induces resistance to cisplatin and paclitaxel, two widely used anticancer agents. The CYP1 B1 overproducing cell line was used to explore if a potent CYP1 B1 specific inhibitor would be able to overcome cisplatin resistance.
Transfection
The plasmid pcDNA3.1/h_CYP1 B1 (Figure 1 ) was used for the transfection of human embryonic kidney HEK-293 cells. The plasmid pcDNA3.1/h_CYP1 B1 was introduced into HEK-293 and CHO cells (1 * 106 cells) via an electroporation device (Nucleofector I, Amaxa GmbH, Cologne, Germany). The Nucleofector I is especially designed to facilitate high efficiency transfections. A specific Nucleofector solution kit that has been developed by Amaxa for HEK-293 and CHO cells was used for transfections. After transfection, cells were expanded in T75 flasks in the presence of 1000 μg/μl of G418 antibiotic. All cell lines, before and after transfection were maintained in the required medium.
After transfection the cell lines were grown for several days and then cell lysates were made. Protein concentrations were determined by Bradford assays and this information was used to perform western blotting so as to confirm the presence of the CYP1 B1 protein.
Western blotting
For Western blotting, cell lysates (12 μg/lane for HEK293 cells and 3 g/lane for CHO-K1 cells) were separated on 10 % SDS-polyacrylamide gels. The proteins were electro- transferred to Immobilon-P-membranes (Millipore) by the semi-dry transfer method. The membranes were blocked with 5 % non-fat dry milk in PBS. The blots were probed first with primary antibody for CYP1 B1 (AbCam, Cat No Ab32649) and the secondary antibody (AbCam, Cat No Ab6721 ); goat polyclonal secondary antibody to rabbit IgG-HyL conjugates to HKP. Chemiluminescence was detected using the Gel Doc (Bio Rad) system using an ECL kit (Abeam, Cat. No. Ab65623).
Western blotting confirmed the presence of the CYP1 B1 protein in HEK-293 and CHO-K1 cells transfected with pcDNA3.1/h_CYP1 B1 plasmid. Proteins from CYP1 B1 Saccharosomes (CYP Design Ltd) were used as positive control. Non-transfected cells were used as negative control. The results are shown in Figure 2.
Based on the results of western blotting it was decided that HEK293 cells transfected with pcDNA3.1/h_CYP1 B1 would be used to carry out further studies.
A2780 and A2780cis are epithelial human ovarian cancer cell lines; A2780 is the parent cell line, whereas A2780cis is a cisplatin-resistant cell line. It was developed by chronic exposure of the parent cisplatin-sensitive A2780 cells to increasing concentrations of cisplatin. It has been reported that cisplatin resistant lines overproduce CYP1 B1. Figure 3 confirms that this is true.
Table 4 depicts the EC50s obtained from MTT assays performed with different cisplatin concentrations (0.05-1 ΟΟμΜ; each concentration in triplicate) to determine the cytotoxicity of cisplatin. The results show that EC50 for cell survival in the presence of cisplatin for a normal or non-transfected HEK-293 cell line is 12μΜ, which is very close to the EC50 obtained in HEK293 cells transfected with the empty pcDNA3.1 plasmid (that contains no CYP1B1 gene). When the HEK293 cell line is transfected with pcDNA3.1/h_CYP1 B1 , the EC50 of cisplatin increased to 61 μΜ (i.e. increase seen in the presence of CYP1 B1 protein). Hence, it can be said that the cytotoxicity of cisplatin decreased in the presence of CYP1 B1 indicating the cells confer resistance to cisplatin in the presence of CYP1 B1 .
Table 4. EC50 data for HEK293 cells, HEK293 cells transfected with pcDNA3.1 and pcDNA3.1/h_CYP1 B1 , and treated with cisplatin. Cell growth was monitored via the MTT assay. EC50 is the concentration of cisplatin that gives half-maximal response to inhibition of cell growth.
Conclusion
We expect that the compounds listed in this application would be re-sensitize HEK-293 cells transferred with pcDNA 3.1/h CYP1 B1 , which are normally resistant to the treatment of cisplatin and paclitaxel.
Claims
1. A compound of formula (I) for use in the prevention and/or treatment of cancer,
(!) wherein each of R1, R2, R3, R4 or R5 are independently selected from hydrogen, aliphatic, alkoxy, thioalkyl, alkylamino, halogen, hydroxy, cyano, nitro, hydroxyalkyl, alkylcarbonyloxy, alkoxycarbonyl, alkylcarbonyl, haloalkyi, alkylsulfonylamino NH2, N02, S02Rx, SORx and COORx, where Rx is hydrogen, aliphatic or aryl.
2. The compound as claimed in claim 1 wherein each of R1, R2, R3, R4 or R5 are independently selected from hydrogen, aliphatic, halogen, hydroxy, alkoxy, thioalkyl, alkylamino or cyano.
3. The compound as claimed in claim 1 or claim 2 wherein one, two or three of R1, R2, R3, R4 or R5 can be substitued with one or more group independently selected from aliphatic, alkoxy, thioalkyl, alkylamino, halogen, hydroxy, cyano, nitro, hydroxyalkyl, alkylcarbonyloxy, alkoxycarbonyl, alkylcarbonyl, haloalkyi, alkylsulfonylamino NH2, N02, S02Rx, SORx and COORx, where Rx is hydrogen, aliphatic or aryl and wherein in the remaining groups are hydrogen.
4. The compound as claimed in any one of claims 1 to 3 wherein each of R1, R2, R3 or R4 are independently hydrogen, hydroxyl or methoxy.
5. The compound as claimed in any preceding claim wherein the phenyl mono-, di- or tri-substituted with hydroxyl or methoxy.
6. The compound as claimed in any preceding claim wherein when R3, R4 and R5 are hydrogen, R1 and R2 are methoxy or hydroxyl.
7. The compound as claimed in any preceding claim selected from
8. The compound of any preceding claim wherein the cancer is a hormone-induced cancer.
9. The compound of claim 5 wherein the cancer is one or more of breast, ovarian, uterine, endometrial and prostate cancer.
10. The compound as claimed in any preceding claim wherein the compound is provided for the prevention and/or treatment of cancer in pre-menopausal women.
A compound of formula (IA)
wherein each of R1, R2, R3, R4 or R5 are independently hydrogen, or methoxy.
12. A compound as claimed in claim 1 1 wherein when R and R and R5 are hydrogen, R1 and R2 are methoxy or hydroxyl.
13. A compound as claimed in claim 1 1 or claim 12 selected from
14. A composition comprising a compound as claimed in any one of claims 1 to 13, in combination with a pharmaceutically acceptable carrier or diluent.
15. A process for the manufacture of a composition as claimed in claim 14 comprising combining a compound as claimed in any one of claims 1 to 13, and a pharmaceutically acceptable carrier or diluent.
16. A method of preventing and/or treating cancer comprising administering a compound as claimed in any one of claims 1 to 13, to a patient in need thereof.
17. The method as claimed in claim 16 for the prevention and/or treatment of hormone-induced cancers.
18. The method as claimed in claim 17 wherein the cancer is one or more of breast, ovarian, uterine, endometrial and prostate cancer.
19. The method as claimed in any one of claims 16 to 18 for the prevention and/or treatment of cancer in pre-menopausal women.
20. The use of the compounds as claimed in any one of claims 1 to 13, in the manufacture of a medicament for the prevention and/or treatment of cancer.
21 . A composition comprising a compound of formula (I) as claimed in any one of claims 1 to 13, and a drug for treating cancer.
22. A composition as claimed in claim 21 wherein the drug for treating cancer is one or more of a platinum compound, such as cisplatin, a taxane or a nucleoside analogue.
23. A composition for treating cancer comprising a compound of formula (I) as claimed in any one of claims 1 to 13, and a drug for treating cancer for use in treating cancer, wherein the cancer is resistant to the cancer treating drug.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1407695.4A GB201407695D0 (en) | 2014-05-01 | 2014-05-01 | Compounds |
GB1407695.4 | 2014-05-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015166042A1 true WO2015166042A1 (en) | 2015-11-05 |
Family
ID=50980426
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2015/059502 WO2015166042A1 (en) | 2014-05-01 | 2015-04-30 | Stilbene derivatives and their use for the treatment of cancer |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB201407695D0 (en) |
WO (1) | WO2015166042A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018136792A1 (en) | 2017-01-20 | 2018-07-26 | The Regents Of The University Of California | Inhibitors of the n-terminal domain of the androgen receptor |
KR101935794B1 (en) | 2016-09-30 | 2019-01-08 | (주)나노믹스 | Inhibitor of function of cyclophilin and use of the same |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991016051A1 (en) * | 1990-04-16 | 1991-10-31 | Rhône-Poulenc Rorer International (Holdings) Inc. | Styryl-substituted monocyclic and bicyclic heteroaryl compounds which inhibit egf receptor tyrosine kinase |
WO1992018481A1 (en) * | 1991-04-16 | 1992-10-29 | Rhone-Poulenc Rorer International (Holdings), Inc. | Styryl-substituted heteroaryl compounds which inhibit egf receptor tyrosine kinase |
EP1864972A1 (en) * | 2005-03-30 | 2007-12-12 | Kabushiki Kaisha Yakult Honsha | Bcrp/abcg2 inhibitor |
-
2014
- 2014-05-01 GB GBGB1407695.4A patent/GB201407695D0/en not_active Ceased
-
2015
- 2015-04-30 WO PCT/EP2015/059502 patent/WO2015166042A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991016051A1 (en) * | 1990-04-16 | 1991-10-31 | Rhône-Poulenc Rorer International (Holdings) Inc. | Styryl-substituted monocyclic and bicyclic heteroaryl compounds which inhibit egf receptor tyrosine kinase |
WO1992018481A1 (en) * | 1991-04-16 | 1992-10-29 | Rhone-Poulenc Rorer International (Holdings), Inc. | Styryl-substituted heteroaryl compounds which inhibit egf receptor tyrosine kinase |
EP1864972A1 (en) * | 2005-03-30 | 2007-12-12 | Kabushiki Kaisha Yakult Honsha | Bcrp/abcg2 inhibitor |
Non-Patent Citations (4)
Title |
---|
KALADHAR B REDDY ET AL: "Inhibition of Breast Cancer Cell Growth in Vitro by a Tyrosine Kinase Inhibitor1", 1 July 1992 (1992-07-01), pages 3636 - 3641, XP055195482, Retrieved from the Internet <URL:http://cancerres.aacrjournals.org/content/52/13/3636.full.pdf> * |
KONDAPAKA B S ET AL: "TYROSINE KINASE INHIBITOR AS A NOVEL SIGNAL TRANSDUCTION AND ANTIPROLIFERATIVE AGENT: PROSTATE CANCER", MOLECULAR AND CELLULAR ENDOCRINOLOGY, ELSEVIER IRELAND LTD, IE, vol. 117, no. 1, 1 March 1996 (1996-03-01), pages 53 - 58, XP001069437, ISSN: 0303-7207, DOI: 10.1016/0303-7207(95)03725-X * |
M. JUDITH PERCINO ET AL: "Spectroscopic characterization of halogen- and cyano-substituted pyridinevinylenes synthesized without catalyst or solvent", CHEMICAL PAPERS, vol. 64, no. 3, 31 March 2010 (2010-03-31), pages 360 - 367, XP055144336, ISSN: 0366-6352, DOI: 10.2478/s11696-010-0012-z * |
WON ET AL: "Kinetics and mechanism of hydrolysis of tyrphostins", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, vol. 104, no. 1, 8 April 1994 (1994-04-08), pages 29 - 40, XP025565411, ISSN: 0378-5173, [retrieved on 19940408], DOI: 10.1016/0378-5173(94)90334-4 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101935794B1 (en) | 2016-09-30 | 2019-01-08 | (주)나노믹스 | Inhibitor of function of cyclophilin and use of the same |
WO2018136792A1 (en) | 2017-01-20 | 2018-07-26 | The Regents Of The University Of California | Inhibitors of the n-terminal domain of the androgen receptor |
US11261152B2 (en) | 2017-01-20 | 2022-03-01 | The Regents Of The University Of California | Inhibitors of the N-terminal domain of the androgen receptor |
Also Published As
Publication number | Publication date |
---|---|
GB201407695D0 (en) | 2014-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113735862B (en) | Nucleoside compound for treating viral infection and application thereof | |
TWI623533B (en) | 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (chk1) inhibitors, and their preparations and applications | |
US7407967B2 (en) | Cyclopamine analogues and methods of use thereof | |
TW201103535A (en) | Carboxylic acid compounds | |
CA3105491C (en) | Selective estrogen receptor degraders | |
JP7237383B2 (en) | Compositions for inhibition of androgen-dependent or -independent prostate cancer cells and pharmaceutical formulations for prostate cancer containing same | |
US10808005B2 (en) | Ligand for orphan nuclear receptor Nur77 and uses thereof | |
US8138361B2 (en) | C-10 carbamates of taxanes | |
WO2015083833A1 (en) | Novel quinazoline derivative | |
WO2015166041A1 (en) | Flavones as cyp1a1 inhibitors for the treatment of cancer | |
WO2015166043A1 (en) | Compounds | |
EP3009424B1 (en) | Bicyclic nitrogen-containing aromatic heterocyclic amide compound | |
WO2015166042A1 (en) | Stilbene derivatives and their use for the treatment of cancer | |
CN104327097A (en) | Triazole derivatives of rapamycin and application | |
WO2023030335A1 (en) | Compound as tyk2/jak1 pseudokinase domain inhibitor, and synthesis and use methods | |
EP4116300A1 (en) | Crystal of tricyclic compound acting on crbn protein and preparation method therefor | |
WO2015166040A2 (en) | Compound | |
CN101016329A (en) | Method of preparing cyclopamine from jervine | |
CN115475253B (en) | Lapatinib-cancer cell stem inhibitor conjugate, preparation method, pharmaceutical composition and application | |
CN109748891B (en) | Docetaxel derivative, pharmaceutical composition and application thereof | |
KR101510995B1 (en) | Pharmaceutical composition for treating or preventing microRNA-31 related diseases | |
US20110039921A1 (en) | Cephalomannine derivatives, their preparation, pharmaceutical composition and use thereof | |
CN111808056B (en) | Dopamine D 2 Receptor selective agonists and their use in the treatment of disease | |
US20240124515A1 (en) | Orally active leukemia inhibitory factor (lif) antagonists for the treatment of cancer | |
KR101634758B1 (en) | A pharmaceutical composition containing 2-hydroxy-7-methyl octahydrophenanthrene derivative as an estrogen receptor ligand or a pharmaceutically acceptable salt thereof as an effective component |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15722960 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15722960 Country of ref document: EP Kind code of ref document: A1 |